Cameron Brink achieves visual freedom with the EVO implantable lenses

Basketball Player

Cam Brink 80 41

Vision struggles on and off the court

Cameron Brink, a star on the women’s basketball team of Stanford University, faced the daily struggles of glasses and contacts, impacting both her personal and professional life.

Cameron Brink High Res v2

EVO ICL: the game-changer

Cameron's vision problems started in the 5th grade when glasses became a part of her daily life. Later, her reliance on visual aids expanded to contacts, introducing a new set of challenges. For approximately 12 years, Cameron navigated the world through glasses and contacts. "I've been wearing glasses or contacts since I was in the 5th grade. And started to struggle with eye dryness and irritation. As a basketball player, I was constantly losing my contacts during games and practice!" The burden of being nearsighted became an accepted norm… until Cameron learned about the EVO Implantable Collamer® Lenses (EVO ICL).
Cameron's decision to correct her nearsightedness with the EVO ICL procedure was fueled by the desire to break free from the constraints of traditional vision correction methods. With EVO ICL, Cameron's life took a remarkable positive turn. "My life has changed for the better! I don't have to fumble with contacts anymore when I wake up or during the day, and my eyes aren't irritated anymore. Plus, I don't have to worry about losing lenses on the court!"
The differences post-EVO ICL are noticeable. In Cameron's words, "my eyes aren't irritated and dry like they were when I wore contacts. And I love waking up in the morning seeing clearly." Cameron emphasizes the life-changing benefits that extend beyond the basketball court. Choosing EVO ICL was not just about vision correction; it was a lifestyle choice. "The time I save each day! Living a life free of contacts was a huge selling point; as well as the fact that the EVO lens implant is reversible if I ever need it."
Cam Brink1
Cam Brink5
Cam Brink6

Join her in experiencing the world with newfound clarity and confidence. For those on the fence about EVO ICL, Cameron passionately encourages,

"Talk to your eye doctor today. It's truly a life-changing procedure!"

Ready to embrace a life without the hassle of glasses and contacts? Discover the possibilities with EVO ICL. Call an EVO advisor today to schedule an appointment with an eye doctor near you, and embark on your own journey towards visual freedom!

이보 ICL로 시력의 자유를 되찾을 준비가 되셨나요? 지금 내 주변에 상담 가능한 안과를 찾아보세요.

내 현재 위치 사용

주요 안전성 정보

ICL은 성인을 대상으로 -0.5D에서 -18.0D 범위의 근시와 6.0D까지의 난시 교정에 대해 승인되었습니다. 21세에서 60세 사이의 성인이 ICL 수술 대상이 됩니다. 안내렌즈삽입술의 성공적인 결과를 위해서는 지난 1년간 시력에 변화가 없어야 합니다. ICL 수술은 안경 및 콘택트렌즈 사용이 필요하지 않도록 시력을 교정합니다. 눈의 노화로 인해 자연적으로 필요한 돋보기 안경은 ICL 안내렌즈삽입술을 받은 후에도 필요할 수 있습니다. ICL은 라식(LASIK), 굴절교정레이저각막절제술(PRK) 및 절개 수술을 포함한 다른 굴절 교정수술법들과 콘택트렌즈 및 안경 등의 시력 교정 방법에 대한 대안이 될 수 있습니다. ICL 안내렌즈삽입술은 외과적 수술이므로 심각한 부작용을 유발할 수도 있습니다. 일반적인 굴절 교정 수술과 관련하여 보고된 발생 가능한 부작용 및 합병증에는 추가적 수술, 백내장 발생, 최대교정시력 손실, 안압 증가, 각막내피세포 손실, 결막 자극, 급성 각막 부종, 지속적 각막 부종, 안내염, 빛번짐, 눈부심, 전방출혈(안구 내 출혈), 전방 축농(안구 내 고름), 염증, 렌즈 탈구, 황반 부종, 동공 무반응, 동공차단 녹내장, 심각한 안내 염증, 홍채염, 포도막염, 유리체 손실 및 각막 이식 등이 있습니다. ICL 수술을 고려하기 전, 정밀 눈 검사를 받은 후 안과 전문의에게 ICL 수술의 장점, 위험요소 및 부작용에 대해 상담 하십시오. 수술 후 회복을 위한 시간에 대해서도 상담하십시오.

참고문헌

국가 또는 지역 선택

Europe

AustriaBelgium - DutchBelgium - FrenchFranceGermanyItalyNetherlandsNorwayPortugalSloveniaSpainSwedenSwitzerlandUK & Ireland

North America

CanadaCanada - FrenchMexicoUnited StatesUnited States - 中文

Latin America

EnglishSpanishPortuguese

North Africa

ArabicFrench

Middle East

Middle East عربىMiddle East - فارسيMiddle East - English

Asia Pacific

AustraliaChina - 中国IndiaJapan - 日本New ZealandS. Korea - 대한민국South East Asia

참고자료

Home - 광고심의필: 조합-2022-04-030 (유효기간: 2025.02.07)

1. Gonzalo Carracedo, et al. The role of dinucleoside polyphosphates on the ocular surface and other eye structures. Prog Retin Eye Res. 2016 Nov;55:182-205. 2. Paul J Dougherty, et al. Refractive outcomes and safety of the implantable collamer lens in young low-to-moderate myopes. Clin Ophthalmol. 2017;11:273–277. 3. Gregory D. Parkhurst, et al. Phakic Intraocular Lens Implantation in United States Military Warfighters: A Retrospective Analysis of Early Clinical Outcomes of the EVO ICL. J Refract Surg. 2011;27(7);473-481. 4. Feingold et al. Biocompatible, optically transparent, ultraviolet light absorbing, polymeric material based upon collagen and method of making. USPTO June 8, 1999. 5. ICL in Treatment of Myopia (ITM) Study Group. Postoperative Inflammation after Implantation of the Implantable Contact Lens. Ophthalmology 2003;110:2335-2341. 6. Steven Schallhorn, MD et al. Night Driving Simulation in a Randomized Prospective Comparison of Visian Toric Implantable Collamer Lenses and Conventional PRK for Moderate to High Myopic Astigmatism. Journal of Refractive Surgery Vol.26, No. 5, 2010:321-326 7. Gregory D Parkhurst. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clinical Ophthalmology 2016;10:1209-1215. 8. Donald R Sanders et al. United States Food and Drug Administration Clinical Trial of the Implantable Collamer Lens (ICL) for Moderate to High Myopia Three-Year Follow-up. Ophthalmology. 2004;111:1683–1692. 9. Elena Martines-plaze, et al. Effect of the EVO + Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life. Am J Ophthalmol. 2021;226:117-125. 10. Data on file. STAAR Surgical Annual Report.

이보 ICL이란? - 광고심의필: 조합-2022-04-031 (유효기간: 2025.02.07)

1. Feingold et al. Biocompatible, optically transparent, ultraviolet light absorbing, polymeric material based upon collagen and method of making. USPTO June 8, 1999. 2. ICL in Treatment of Myopia (ITM) Study Group. Postoperative Inflammation after Implantation of the Implantable Contact Lens. Ophthalmology 2003;110:2335-2341. 3. Risto J. Uusitalo, et al. Implantable contact lens for high myopia. J Cataract Refract Surg 2002(28):29-36. 4. Gregory D. Parkhurst, et al. Phakic Intraocular Lens Implantation in United States Military Warfighters: A Retrospective Analysis of Early Clinical Outcomes of the EVO ICL. J Refract Surg. 2011;27(7);473-481. 5. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24) 6. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851. 7. Steven Schallhorn, MD et al. Night Driving Simulation in a Randomized Prospective Comparison of Visian Toric Implantable Collamer Lenses and Conventional PRK for Moderate to High Myopic Astigmatism. Journal of Refractive Surgery Vol.26, No. 5, 2010:321-326. 8. Gregory D Parkhurst. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clinical Ophthalmology 2016;10:1209-1215. 9. Donald R Sanders et al. United States Food and Drug Administration Clinical Trial of the Implantable Collamer Lens (ICL) for Moderate to High Myopia Three-Year Follow-up. Ophthalmology. 2004;111:1683–1692.

이보 ICL의 장점(야간시력 개선) - 광고심의필: 조합-2022-04-032 (유효기간: 2025.02.07)

1. Steven Schallhorn, MD et al. Night Driving Simulation in a Randomized Prospective Comparison of Visian Toric Implantable Collamer Lenses and Conventional PRK for Moderate to High Myopic Astigmatism. Journal of Refractive Surgery Vol.26, No. 5, 2010:321-326. 2. Gregory D Parkhurst. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clinical Ophthalmology 2016;10:1209-1215. 3. Donald R Sanders et al. United States Food and Drug Administration Clinical Trial of the Implantable Collamer Lens (ICL) for Moderate to High Myopia Three-Year Follow-up. Ophthalmology. 2004;111:1683–1692. 4. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24) 5. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851.

이보 ICL의 장점(안구건조증이 걱정되세요?) - 광고심의필: 조합-2022-04-033 (유효기간: 2025.02.08)

1. Gregory D. Parkhurst, et al. Phakic Intraocular Lens Implantation in United States Military Warfighters: A Retrospective Analysis of Early Clinical Outcomes of the EVO ICL. J Refract Surg. 2011;27(7);473-481. 2. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24). 3. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851.

이보 ICL의 장점(마치 내 눈 같은 편안함) - 광고심의필: 조합-2022-04-029 (유효기간: 2025.02.03)

1. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24). 2. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851.

수술 과정 - 광고심의필: 조합-2022-04-034 (유효기간: 2025.02.03)

1. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24) 2. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851. 3. Elena Martines-plaze, et al. Effect of the EVO + Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life. Am J Ophthalmol. 2021;226:117-125. 4. Data on file. STAAR Surgical Annual Report.

자주 묻는 질문 - 광고심의필: 조합-2022-04-035 (유효기간: 2025.02.03)

1. Feingold et al. Biocompatible, optically transparent, ultraviolet light absorbing, polymeric material based upon collagen and method of making. USPTO June 8, 1999. 2. ICL in Treatment of Myopia (ITM) Study Group. Postoperative Inflammation after Implantation of the Implantable Contact Lens. Ophthalmology 2003;110:2335-2341. 3. Risto J. Uusitalo, et al. Implantable contact lens for high myopia. J Cataract Refract Surg 2002(28):29-36. 4. Elena Martines-plaze, et al. Effect of the EVO + Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life. Am J Ophthalmol. 2021;226:117-125.

개인정보 수집 및 이용

이보 ICL 브로슈어 발송을 위한 최소한의 개인정보를 수집하고 이용합니다.

수집된 정보는 이메일 발송 외 다른 목적으로 이용되지 않으며, 서비스가 종료되거나 구독을 해지할 경우 즉시 파기됩니다.

    * 이보ICL의 제품명은 EVO(+) VisianICL(VICL), EVO(+) VisianToricICL(VTICL)입니다.
    References 1. Mark Packer. The EVO ICL for Moderate Myopia: Results from the US FDA Clinical Trial. Clinical Ophthalmology. 2022. 3981-3991. 2. Ganesh, Sri et al. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clinical ophthalmology 2017:11 1253–1263. 3. FDA. Before, During& After Surgery. https://www.fda.gov/medical-devices/phakic-intraocular-lenses/during-after-surgery (as of 2021-12-24) 4. 윤재문외. 난시교정용후방유수정체안내렌즈삽입술의단기간임상성적. 대한안과학회지. 2009;50(6):839-851. 5. Akihito Igarashi. Posterior chamber phakic IOLs vs. LASIK: benefits and complications. Expert Review ofOphthalmology. 2019:14 43–52. 6. U.S. Food and Drug Administration, Center for Devices and Radiological Health. Approval Letter, March 25, 2022. FDA. https://www.accessdata.fda.gov/cdrh_docs/pdf3/P030016S035A.pdf. 7. Packer M. Evaluation of the EVO/EVO+ Sphere and ToricVisianICL: Six Month Results from the United States Food and Drug Administration Clinical Trial. Clinical Ophthalmology. 2022;16:1541-53. 8. Feingold et al. Biocompatible, optically transparent, ultraviolet light absorbing, polymeric material based upon collagen and method of making. USPTO June 8, 1999. 9. Gregory D. Parkhurst, et al. Phakic Intraocular Lens Implantation in United States Military Warfighters: A Retrospective Analysis of Early Clinical Outcomes of the EVO ICL. J Refract Surg. 2011;27(7);473-48. 10. Steven Schallhorn, MD et al. Night Driving Simulation in a Randomized Prospective Comparison of VisianToricImplantable CollamerLenses and Conventional PRK for Moderate to High Myopic Astigmatism. Journal of Refractive Surgery Vol.26, No. 5, 2010:321-326. 11. Gregory D Parkhurst. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clinical Ophthalmology 2016;10:1209-1215.

    ※ 이 제품은 ‘의료기기-유수정체인공수정체’이며, 수술을 원하실 경우 안과에 방문하셔서 추가 주의사항 및 수술 관련 내용을 확인하십시오.
    광고심의필: 심의번호 32023-|10-04-0326 (유효기간: 2026.02.10)
    광고심의필: 조합-2022-04-029 l 조합-2022-04-034 l 조합-2022-04-035 (유효기간: 2025.02.03)
    광고심의필: 조합-2022-04-030 l 조합-2022-04-031 l 조합-2022-04-032 (유효기간: 2025.02.07) | 광고심의필: 조합-2022-04-033 (유효기간: 2025.02.08)

    © 2024 STAAR Surgical®. ALL RIGHTS RESERVED.